1	Short	Short	B-NP	JJ	O	5	NMOD	0
2	pigment	pigment	I-NP	NN	O	5	NMOD	0
3	epithelial-derived	epithelial-derived	I-NP	JJ	O	5	NMOD	0
4	factor-derived	factor-derived	I-NP	JJ	O	5	NMOD	0
5	peptide	peptide	I-NP	NN	O	6	SUB	0
6	inhibits	inhibit	B-VP	VBZ	O	0	ROOT	18	inhibits
7	angiogenesis	angiogenesis	B-NP	NN	O	10	NMOD	3	angiogenesis
8	and	and	I-NP	CC	O	10	NMOD	0
9	tumor	tumor	I-NP	NN	O	10	NMOD	0
10	growth	growth	I-NP	NN	O	6	OBJ	4	growth
11	.	.	O	.	O	6	P	0

1	PURPOSE	PURPOSE	B-NP	NN	O	5	NMOD	0
2	:	:	O	:	O	1	P	0
3	Pigment	Pigment	B-NP	NN	B-protein	5	NMOD	0
4	epithelial-derived	epithelial-derived	I-NP	JJ	I-protein	5	NMOD	0
5	factor	factor	I-NP	NN	I-protein	9	SUB	0
6	(	(	O	(	O	8	DEP	0
7	PEDF	PEDF	B-NP	NN	B-protein	8	DEP	0
8	)	)	O	)	O	5	NMOD	0
9	is	be	B-VP	VBZ	O	0	ROOT	0
10	a	a	B-NP	DT	O	13	NMOD	0
11	potent	potent	I-NP	JJ	O	13	NMOD	0
12	angiogenesis	angiogenesis	I-NP	NN	O	13	NMOD	3	angiogenesis
13	inhibitor	inhibitor	I-NP	NN	O	9	PRD	0
14	with	with	B-PP	IN	O	13	NMOD	0
15	multiple	multiple	B-NP	JJ	O	17	NMOD	0
16	other	other	I-NP	JJ	O	17	NMOD	0
17	functions	function	I-NP	NNS	O	14	PMOD	0
18	,	,	O	,	O	9	P	0
19	some	some	B-NP	DT	O	20	NMOD	0
20	of	of	B-PP	IN	O	9	VMOD	0
21	which	which	B-NP	WDT	O	20	PMOD	0
22	enhance	enhance	B-VP	VBP	O	21	SBAR	17	enhance
23	tumor	tumor	B-NP	NN	O	24	NMOD	0
24	growth	growth	I-NP	NN	O	22	OBJ	4	growth
25	.	.	O	.	O	9	P	0

1	Our	Our	B-NP	PRP$	O	3	NMOD	0
2	previous	previous	I-NP	JJ	O	3	NMOD	0
3	studies	study	I-NP	NNS	O	4	SUB	0
4	mapped	map	B-VP	VBD	O	0	ROOT	0
5	PEDF	PEDF	B-NP	NN	B-protein	9	NMOD	0
6	antiangiogenic	antiangiogenic	I-NP	JJ	O	9	NMOD	3	angiogenic
7	and	and	I-NP	CC	O	9	NMOD	0
8	prosurvival	prosurvival	I-NP	NN	O	9	NMOD	0
9	activities	activity	I-NP	NNS	O	4	OBJ	18	activities
10	to	to	B-PP	TO	O	4	VMOD	0
11	distinct	distinct	B-NP	JJ	O	12	NMOD	0
12	epitopes	epitope	I-NP	NNS	B-protein	10	PMOD	0
13	.	.	O	.	O	4	P	0

1	This	This	B-NP	DT	O	2	NMOD	0
2	study	study	I-NP	NN	O	3	SUB	0
3	was	be	B-VP	VBD	O	0	ROOT	0
4	aimed	aim	I-VP	VBN	O	3	VC	0
5	to	to	B-VP	TO	O	6	VMOD	0
6	determine	determine	I-VP	VB	O	4	VMOD	0
7	the	the	B-NP	DT	O	9	NMOD	0
8	minimal	minimal	I-NP	JJ	O	9	NMOD	0
9	fragment	fragment	I-NP	NN	O	6	OBJ	0
10	of	of	B-PP	IN	O	9	NMOD	0
11	PEDF	PEDF	B-NP	NN	B-protein	10	PMOD	0
12	,	,	O	,	O	11	P	0
13	which	which	B-NP	WDT	O	11	NMOD	0
14	maintains	maintain	B-VP	VBZ	O	13	SBAR	0
15	antiangiogenic	antiangiogenic	B-NP	JJ	O	17	AMOD	3	angiogenic
16	and	and	I-NP	CC	O	17	AMOD	0
17	antitumor	antitumor	I-NP	JJ	O	18	NMOD	0
18	efficacy	efficacy	I-NP	NN	O	14	OBJ	18	efficacy
19	.	.	O	.	O	3	P	0

1	EXPERIMENTAL	EXPERIMENTAL	B-NP	JJ	O	2	NMOD	0
2	DESIGN	DESIGN	I-NP	NN	O	0	ROOT	0
3	:	:	O	:	O	2	P	0
4	We	We	B-NP	PRP	O	5	SUB	0
5	analyzed	analyze	B-VP	VBD	O	2	NMOD	0
6	antigenicity	antigenicity	B-NP	NN	O	12	NMOD	0
7	,	,	O	,	O	12	P	0
8	hydrophilicity	hydrophilicity	B-NP	NN	O	12	NMOD	0
9	,	,	O	,	O	12	P	0
10	and	and	O	CC	O	12	NMOD	0
11	charge	charge	B-NP	NN	O	12	NMOD	0
12	distribution	distribution	I-NP	NN	O	5	OBJ	0
13	of	of	B-PP	IN	O	12	NMOD	0
14	the	the	B-NP	DT	O	16	NMOD	0
15	angioinhibitory	angioinhibitory	I-NP	JJ	O	16	NMOD	3	angioinhibitory
16	epitope	epitope	I-NP	NN	O	13	PMOD	0
17	(	(	O	(	O	20	DEP	0
18	the	the	B-NP	DT	O	19	NMOD	0
19	34-mer	34-mer	I-NP	NN	O	20	DEP	0
20	)	)	O	)	O	16	NMOD	0
21	and	and	O	CC	O	5	VMOD	0
22	designed	design	B-VP	VBN	O	5	VMOD	0
23	three	three	B-NP	CD	O	24	NMOD	0
24	peptides	peptide	I-NP	NNS	O	22	OBJ	0
25	covering	cover	B-VP	VBG	O	24	NMOD	0
26	its	its	B-NP	PRP$	O	28	NMOD	0
27	COOH	COOH	I-NP	NN	B-protein	28	NMOD	0
28	terminus	terminus	I-NP	NN	I-protein	35	NMOD	0
29	,	,	O	,	O	35	P	0
30	P14	P14	B-NP	NN	B-protein	35	NMOD	0
31	,	,	O	,	O	35	P	0
32	P18	P18	B-NP	NN	B-protein	35	NMOD	0
33	,	,	O	,	O	35	P	0
34	and	and	O	CC	O	35	NMOD	0
35	P23	P23	B-NP	NN	B-protein	25	OBJ	0
36	.	.	O	.	O	2	P	0

1	We	We	B-NP	PRP	O	2	SUB	0
2	analyzed	analyze	B-VP	VBD	O	0	ROOT	0
3	their	their	B-NP	PRP$	O	4	NMOD	0
4	ability	ability	I-NP	NN	O	2	OBJ	0
5	to	to	B-VP	TO	O	6	VMOD	0
6	block	block	I-VP	VB	O	4	NMOD	18	block
7	endothelial	endothelial	B-NP	JJ	B-cell_type	9	NMOD	0
8	cell	cell	I-NP	NN	I-cell_type	9	NMOD	0
9	chemotaxis	chemotaxis	I-NP	NN	O	6	OBJ	14	chemotaxis
10	and	and	O	CC	O	2	VMOD	0
11	induce	induce	B-VP	VB	O	2	VMOD	17	induce
12	apoptosis	apoptosis	B-NP	NN	O	11	OBJ	5	apoptosis
13	in	in	B-ADVP	FW	O	11	VMOD	0
14	vitro	vitro	I-ADVP	FW	O	13	AMOD	0
15	and	and	O	CC	O	11	VMOD	0
16	their	their	B-NP	PRP$	O	18	NMOD	0
17	antiangiogenic	antiangiogenic	I-NP	JJ	O	18	NMOD	3	angiogenic
18	activity	activity	I-NP	NN	O	11	OBJ	18	activity
19	in	in	B-ADVP	FW	O	18	NMOD	0
20	vivo	vivo	I-ADVP	FW	O	19	AMOD	0
21	.	.	O	.	O	2	P	0

1	The	The	B-NP	DT	O	3	NMOD	0
2	selected	select	I-NP	VBN	O	3	NMOD	0
3	peptide	peptide	I-NP	NN	O	4	SUB	0
4	was	be	B-VP	VBD	O	0	ROOT	0
5	tested	test	I-VP	VBN	O	4	VC	0
6	for	for	B-PP	IN	O	5	VMOD	0
7	the	the	B-NP	DT	O	9	NMOD	0
8	antitumor	antitumor	I-NP	JJ	O	9	NMOD	0
9	activity	activity	I-NP	NN	O	21	NMOD	18	activity
10	against	against	B-PP	IN	O	9	NMOD	0
11	mildly	mildly	B-NP	RB	O	12	AMOD	0
12	aggressive	aggressive	I-NP	JJ	O	15	NMOD	0
13	xenografted	xenografte	I-NP	VBN	O	15	NMOD	19	xenografted
14	prostate	prostate	I-NP	NN	O	15	NMOD	0
15	carcinoma	carcinoma	I-NP	NN	O	10	PMOD	0
16	and	and	O	CC	O	21	NMOD	0
17	highly	highly	B-NP	RB	O	18	AMOD	0
18	aggressive	aggressive	I-NP	JJ	O	21	NMOD	0
19	renal	renal	I-NP	JJ	O	21	NMOD	0
20	cell	cell	I-NP	NN	O	21	NMOD	0
21	carcinoma	carcinoma	I-NP	NN	O	6	PMOD	0
22	.	.	O	.	O	4	P	0

1	To	To	B-VP	TO	O	2	VMOD	0
2	verify	verify	I-VP	VB	O	14	VMOD	0
3	that	that	B-SBAR	IN	O	2	VMOD	0
4	P18	P18	B-NP	NN	B-protein	5	SUB	0
5	acts	act	B-VP	VBZ	O	3	SBAR	0
6	in	in	B-PP	IN	O	5	VMOD	0
7	the	the	B-NP	DT	O	9	NMOD	0
8	same	same	I-NP	JJ	O	9	NMOD	0
9	manner	manner	I-NP	NN	O	6	PMOD	0
10	as	as	B-PP	IN	O	5	VMOD	0
11	PEDF	PEDF	B-NP	NN	B-protein	10	PMOD	0
12	,	,	O	,	O	14	P	0
13	we	we	B-NP	PRP	O	14	SUB	0
14	used	use	B-VP	VBD	O	0	ROOT	0
15	immunohistochemistry	immunohistochemistry	B-NP	NN	O	14	OBJ	0
16	to	to	B-VP	TO	O	17	VMOD	0
17	measure	measure	I-VP	VB	O	14	VMOD	0
18	PEDF	PEDF	B-NP	NN	B-protein	19	NMOD	0
19	targets	target	I-NP	NNS	I-protein	31	NMOD	0
20	,	,	O	,	O	31	P	0
21	vascular	vascular	B-NP	JJ	B-protein	25	NMOD	0
22	endothelial	endothelial	I-NP	JJ	I-protein	25	NMOD	0
23	growth	growth	I-NP	NN	I-protein	25	NMOD	0
24	factor	factor	I-NP	NN	I-protein	25	NMOD	0
25	receptor	receptor	I-NP	NN	I-protein	31	NMOD	0
26	2	2	B-NP	CD	I-protein	25	NMOD	0
27	,	,	O	,	O	31	P	0
28	and	and	O	CC	O	31	NMOD	0
29	CD95	CD95	B-NP	NN	B-protein	30	NMOD	0
30	ligand	ligand	I-NP	NN	I-protein	31	NMOD	0
31	expression	expression	I-NP	NN	O	17	OBJ	9	expression
32	in	in	B-PP	IN	O	31	NMOD	0
33	P18-treated	P18-treated	B-NP	JJ	O	34	NMOD	19	treated
34	vasculature	vasculature	I-NP	NN	O	32	PMOD	0
35	.	.	O	.	O	14	P	0

1	RESULTS	RESULTS	B-NP	NNS	O	14	SUB	0
2	:	:	O	:	O	1	P	0
3	P14	P14	B-NP	NN	B-protein	5	NMOD	0
4	and	and	I-NP	CC	O	5	NMOD	0
5	P18	P18	I-NP	NN	B-protein	6	SUB	0
6	blocked	block	B-VP	VBD	O	14	VMOD	18	blocked
7	endothelial	endothelial	B-NP	JJ	O	9	NMOD	0
8	cell	cell	I-NP	NN	O	9	NMOD	0
9	chemotaxis	chemotaxis	I-NP	NN	O	6	OBJ	14	chemotaxis
10	;	;	O	:	O	6	P	0
11	P18	P18	B-NP	NN	B-protein	13	NMOD	0
12	and	and	I-NP	CC	O	13	NMOD	0
13	P23	P23	I-NP	NN	B-protein	14	SUB	0
14	induced	induce	B-VP	VBD	O	0	ROOT	17	induced
15	apoptosis	apoptosis	B-NP	NN	O	14	OBJ	5	apoptosis
16	.	.	O	.	O	14	P	0

1	P18	P18	B-NP	NN	B-protein	2	SUB	0
2	showed	show	B-VP	VBD	O	13	VMOD	0
3	the	the	B-NP	DT	O	5	NMOD	0
4	highest	high	I-NP	JJS	O	5	NMOD	0
5	IC50	IC50	I-NP	NN	O	2	OBJ	0
6	and	and	O	CC	O	2	VMOD	0
7	blocked	block	B-VP	VBD	O	2	VMOD	18	blocked
8	angiogenesis	angiogenesis	B-NP	NN	O	7	OBJ	3	angiogenesis
9	in	in	B-ADVP	FW	O	7	VMOD	0
10	vivo	vivo	I-ADVP	FW	O	9	AMOD	0
11	:	:	O	:	O	13	P	0
12	P23	P23	B-NP	NN	B-protein	13	SUB	0
13	was	be	B-VP	VBD	O	17	VMOD	0
14	inactive	inactive	B-ADJP	JJ	O	13	PRD	18	inactive
15	and	and	O	CC	O	17	VMOD	0
16	P14	P14	B-NP	NN	B-protein	17	SUB	0
17	was	be	B-VP	VBD	O	0	ROOT	0
18	proangiogenic	proangiogenic	B-ADJP	JJ	O	17	PRD	3	angiogenic
19	.	.	O	.	O	17	P	0

1	P18	P18	B-NP	NN	B-protein	2	SUB	0
2	increased	increase	B-VP	VBD	O	0	ROOT	17	increased
3	the	the	B-NP	DT	O	4	NMOD	0
4	production	production	I-NP	NN	O	2	OBJ	9	production
5	of	of	B-PP	IN	O	4	NMOD	0
6	CD95	CD95	B-NP	NN	B-protein	7	NMOD	0
7	ligand	ligand	I-NP	NN	I-protein	5	PMOD	0
8	and	and	O	CC	O	2	VMOD	0
9	reduced	reduce	B-VP	VBD	O	2	VMOD	18	reduced
10	the	the	B-NP	DT	O	11	NMOD	0
11	expression	expression	I-NP	NN	O	9	OBJ	9	expression
12	of	of	B-PP	IN	O	11	NMOD	0
13	vascular	vascular	B-NP	JJ	B-protein	17	NMOD	0
14	endothelial	endothelial	I-NP	JJ	I-protein	17	NMOD	0
15	growth	growth	I-NP	NN	I-protein	17	NMOD	0
16	factor	factor	I-NP	NN	I-protein	17	NMOD	0
17	receptor	receptor	I-NP	NN	I-protein	12	PMOD	0
18	2	2	B-NP	CD	I-protein	17	NMOD	0
19	by	by	B-PP	IN	O	9	VMOD	0
20	the	the	B-NP	DT	O	22	NMOD	0
21	endothelial	endothelial	I-NP	JJ	B-cell_type	22	NMOD	0
22	cells	cell	I-NP	NNS	I-cell_type	19	PMOD	0
23	in	in	B-ADVP	FW	O	9	VMOD	0
24	vivo	vivo	I-ADVP	FW	O	23	AMOD	0
25	.	.	O	.	O	2	P	0

1	In	In	B-PP	IN	O	6	VMOD	0
2	tumor	tumor	B-NP	NN	O	3	NMOD	0
3	studies	study	I-NP	NNS	O	1	PMOD	0
4	,	,	O	,	O	6	P	0
5	P18	P18	B-NP	NN	B-protein	6	SUB	0
6	was	be	B-VP	VBD	O	0	ROOT	0
7	more	more	B-ADJP	RBR	O	8	AMOD	0
8	effective	effective	I-ADJP	JJ	O	6	PRD	0
9	in	in	B-PP	IN	O	8	AMOD	0
10	blocking	block	B-VP	VBG	O	9	PMOD	18	blocking
11	the	the	B-NP	DT	O	14	NMOD	0
12	angiogenesis	angiogenesis	I-NP	NN	O	14	NMOD	3	angiogenesis
13	and	and	I-NP	CC	O	14	NMOD	0
14	growth	growth	I-NP	NN	O	10	OBJ	4	growth
15	of	of	B-PP	IN	O	14	NMOD	0
16	the	the	B-NP	DT	O	18	NMOD	0
17	prostate	prostate	I-NP	NN	O	18	NMOD	0
18	cancer	cancer	I-NP	NN	O	15	PMOD	0
19	than	than	B-PP	IN	O	10	VMOD	0
20	parental	parental	B-NP	JJ	O	21	NMOD	0
21	34-mer	34-mer	I-NP	NN	O	19	PMOD	0
22	;	;	O	:	O	6	P	0
23	in	in	B-PP	IN	O	6	VMOD	0
24	the	the	B-NP	DT	O	27	NMOD	0
25	renal	renal	I-NP	JJ	O	27	NMOD	0
26	cell	cell	I-NP	NN	O	27	NMOD	0
27	carcinoma	carcinoma	I-NP	NN	O	29	NMOD	0
28	,	,	O	,	O	29	P	0
29	P18	P18	B-NP	NN	B-protein	23	PMOD	0
30	strongly	strongly	B-ADVP	RB	O	6	VMOD	0
31	decreased	decrease	B-VP	VBD	O	6	VMOD	18	decreased
32	angiogenesis	angiogenesis	B-NP	NN	O	31	OBJ	3	angiogenesis
33	and	and	O	CC	O	6	VMOD	0
34	halted	halt	B-VP	VBD	O	6	VMOD	18	halted
35	the	the	B-NP	DT	O	36	NMOD	0
36	progression	progression	I-NP	NN	O	34	OBJ	17	progression
37	of	of	B-PP	IN	O	36	NMOD	0
38	established	establish	B-NP	VBN	O	39	NMOD	0
39	tumors	tumor	I-NP	NNS	O	37	PMOD	0
40	.	.	O	.	O	6	P	0

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	0
3	P18	P18	B-NP	NN	B-protein	4	SUB	0
4	is	be	B-VP	VBZ	O	1	NMOD	0
5	a	a	B-NP	DT	O	11	NMOD	0
6	novel	novel	I-NP	JJ	O	10	AMOD	0
7	and	and	I-NP	CC	O	10	AMOD	0
8	potent	potent	I-NP	JJ	O	10	AMOD	0
9	antiangiogenic	antiangiogenic	I-NP	JJ	O	10	AMOD	3	angiogenic
10	biotherapeutic	biotherapeutic	I-NP	JJ	O	11	NMOD	0
11	agent	agent	I-NP	NN	O	4	PRD	0
12	that	that	B-NP	WDT	O	11	NMOD	0
13	has	have	B-VP	VBZ	O	12	SBAR	0
14	potential	potential	B-ADJP	JJ	O	13	VMOD	0
15	to	to	B-VP	TO	O	16	VMOD	0
16	be	be	I-VP	VB	O	14	AMOD	0
17	developed	develop	I-VP	VBN	O	16	VC	0
18	for	for	B-PP	IN	O	17	VMOD	0
19	the	the	B-NP	DT	O	20	NMOD	0
20	treatment	treatment	I-NP	NN	O	18	PMOD	19	treatment
21	of	of	B-PP	IN	O	20	NMOD	0
22	prostate	prostate	B-NP	NN	O	25	NMOD	0
23	and	and	O	CC	O	25	NMOD	0
24	renal	renal	B-NP	JJ	O	25	NMOD	0
25	cancer	cancer	I-NP	NN	O	21	PMOD	0
26	.	.	O	.	O	1	P	0

